Accessibility Menu
 
Krystal Biotech logo

Krystal Biotech

(NASDAQ) KRYS

Current Price$254.93
Market Cap$7.22B
Since IPO (2017)+2,222%
5 Year+270%
1 Year+33%
1 Month-7%

Krystal Biotech Financials at a Glance

Market Cap

$7.22B

Revenue (TTM)

$389.13M

Net Income (TTM)

$204.83M

EPS (TTM)

$6.84

P/E Ratio

36.10

Dividend

$0.00

Beta (Volatility)

1.28 (Average)

Price

$254.93

Volume

240,463.76

Open

$251.04

Previous Close

$254.95

Daily Range

$250.91 - $257.65

52-Week Range

$122.80 - $298.30

KRYS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Krystal Biotech

Industry

Biotechnology

Employees

295

CEO

Krish S. Krishnan, MBA

Headquarters

Pittsburgh, PA 15203, US

KRYS Financials

Key Financial Metrics (TTM)

Gross Margin

93%

Operating Margin

41%

Net Income Margin

53%

Return on Equity

19%

Return on Capital

13%

Return on Assets

15%

Earnings Yield

2.77%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.22B

Shares Outstanding

29.23M

Volume

240.46K

Short Interest

0.00%

Avg. Volume

295.90K

Financials (TTM)

Gross Profit

$360.36M

Operating Income

$161.29M

EBITDA

$167.85M

Operating Cash Flow

$200.87M

Capital Expenditure

$11.95M

Free Cash Flow

$188.91M

Cash & ST Invst.

$827.79M

Total Debt

$9.34M

Krystal Biotech Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$107.11M

+17.5%

Gross Profit

$96.19M

+11.6%

Gross Margin

89.81%

N/A

Market Cap

$7.22B

N/A

Market Cap/Employee

$26.27M

N/A

Employees

275

N/A

Net Income

$51.40M

+13.0%

EBITDA

$39.61M

-7.7%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$818.45M

+38.7%

Accounts Receivable

$127.42M

+21.7%

Inventory

$40.48M

+52.7%

Long Term Debt

$7.57M

+25.2%

Short Term Debt

$1.77M

+45.5%

Return on Assets

15.36%

N/A

Return on Invested Capital

13.10%

N/A

Free Cash Flow

$75.37M

+44.8%

Operating Cash Flow

$77.51M

+46.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MTSRMetsera, Inc.
$70.50-0.35%
ACLXArcellx, Inc.
$114.54-0.13%
PTGXProtagonist Therapeutics, Inc.
$104.31+3.90%
PCVXVaxcyte, Inc.
$55.91+2.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$10.31-0.03%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.31-0.04%
TERNTerns Pharmaceuticals
$52.86+0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$44.39+0.02%

Questions About KRYS

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.